Conclusion of non-exclusive discount agreements in accordance with §§ 130a Paragraph 8/130c Paragraph 1 SGB V for drugs with the active ingredient omalizumab (R03DX05) as part of a so-called open house model.

AOK Rhineland-Palatinate Saarland - The health insurance company Germany has Released a tender for Conclusion of non-exclusive discount agreements in accordance with §§ 130a Paragraph 8/130c Paragraph 1 SGB V for drugs with the active ingredient omalizumab (R03DX05) as part of a so-called open house model. in Pharmaceuticals. The tender was released on Jun 22, 2023.

Country - Germany

Summary - Conclusion of non-exclusive discount agreements in accordance with §§ 130a Paragraph 8/130c Paragraph 1 SGB V for drugs with the active ingredient omalizumab (R03DX05) as part of a so-called open house model.

Deadline - May 31, 2025

GT reference number - 67876844

Product classification - Pharmaceutical products